Combination of congenital anomalies, socioeconomic deprivation impacts children’s school successNovember 3, 2026
General Drug combination delivers promising survival gains in advanced endometrial cancerBy Healthcare Propulsion StaffOctober 25, 20260 An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or…
